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A B S T R A C T
The in vitro activity of tigecycline was evaluated
against baseline pathogens isolated from patients
enrolled in phase 3 clinical trials for community-
acquired pneumonia conducted in 29 countries
worldwide. Tigecycline was active against the
most prevalent pathogens, including Streptococcus
pneumoniae (MIC90 0.06 mg ⁄L), Staphylococcus
aureus (MIC90 0.25 mg ⁄L), Haemophilus influenzae
(MIC90 0.5 mg ⁄L) and Klebsiella pneumoniae
(MIC90 1 mg ⁄L). Twelve isolates of S. pneumoniae
expressing tet(M) and two isolates of K. pneumo-
niae producing extended-spectrum b-lactamases
isolated during the study were susceptible to
tigecycline. The excellent in vitro activity of tige-
cycline against these clinical isolates confirmed its
potential utility against pathogens associated with
community-acquired pneumonia.
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Tigecycline, the 9-t-butylglycylamido derivative
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response to the worldwide threat of emerging
resistance to antibiotics [1]. Tigecycline demon-
strates activity against a broad range of pathogens,
including: methicillin-resistant Staphylococcus aur-
eus (MRSA), vancomycin-resistant Enterococcus
faecalis and E. faecium and penicillin-resistant
Streptococcus pneumoniae; Gram-negative patho-
gens, including extended-spectrum b-lactamase
(ESBL)-producing Escherichia coli and Klebsiella
pneumoniae; anaerobic bacteria, including the Bac-
teroides fragilis group; and atypical bacteria,
including Mycoplasma spp., Chlamydia spp. and
rapidly growing Mycobacteria spp. [2–7]. Tigecy-
cline was approved in 2005 for use in complicated
skin and skin structure infections and complicated
intra-abdominal infections. Subsequently, two
pivotal phase 3 clinical trials were conducted for
the treatment of community-acquired pneumonia
in which tigecycline was shown to be safe and
effective (Dukart G, Dartois N, Cooper CA,
Gandjini H, Ellis-Grosse EJ. Integrated results of
2 phase 3 studies comparing tigecycline with
levofloxacin in patients with community-acquired
pneumonia. 46th Interscience Conference on Anti-
microbial Agents and Chemotherapy, San Fran-
cisco, CA, 27–30 September 2006; Abstract L-1450).
The purpose of the present analysis was to
compare the susceptibility of the clinical isolates
from patients with community-acquired pneumo-
nia to tigecycline and comparative agents.
Isolates from all patients enrolled in either the
tigecycline group or comparator treatment group
were used in this analysis. Only baseline patho-
gens from respiratory specimens judged to be
adequate by Gram stain (>100 polymorphonuclear
neutrophils ⁄ low power field (lpf) and <10 squa-
mous cells ⁄ lpf) were included in the analysis.
Susceptibility tests were performed by broth mic-
rodilution, using methods recommended by the
CLSI [8]. MICs were determined in Mueller–
Hinton II broth (MHB) for most organisms. For
streptococci and Haemophilus spp., MIC determi-
nations were performed in MHB containing 5%
lysed horse blood and Haemophilus test medium,
respectively. Methicillin resistance of staphylo-
cocci was determined by MIC tests for oxacillin
supplemented with 2% NaCl [8,9].
The clinical trials for community-acquired
pneumonia enrolled 846 patients who were from
116 investigational sites in 29 countries in North
America, Latin America, western Europe, eastern
Europe, Asia and South Africa. Microbiological
cultures from respiratory samples yielded 456
baseline isolates. The most prevalent pathogens
isolated were S. pneumoniae, Haemophilus influen-
zae, Staphylococcus aureus and K. pneumoniae. The
distribution of pathogens was typical for this type
of infection [10,11].
The susceptibility of pathogens isolated in the
clinical trials to tigecycline and comparative
antibiotics is shown in Table 1. All of the strains
of S. pneumoniae that were tested were inhibited
by tigecycline at a concentration of 0.12 mg ⁄L or
less. These results were similar to the results
obtained previously, in that the MIC90 for tigecy-
cline (0.06 mg ⁄L) against S. pneumoniae isolates
from these clinical trials was identical to that
obtained in a multi-laboratory preclinical study
[12]. Tigecycline was active against all strains of
S. pneumoniae, regardless of the susceptibility to
penicillin. All of the pneumococci were suscepti-
ble to levofloxacin, imipenem and linezolid; how-
ever, a wide range of MICs of minocycline,
tetracycline and azithromycin were obtained. In
addition, the susceptibility data for tigecycline
with the most prevalent pathogens from the
phase 3 clinical trials were also analyzed for
regional variability. For S. pneumoniae, the mode
and MIC90 values for tigecycline were 0.06 mg ⁄L
for all of the strains isolated from patients in
various regions of the world. These results are in
agreement with results obtained previously from
a number of large in vitro susceptibility studies
that included isolates from North America, Latin
America, Europe, the Middle East and Asia [2,
13–15]. Furthermore, S. pneumoniae isolates with a
tetracycline MIC ‡8 mg ⁄L were subjected to PCR
for determination of the tetracycline resistance
determinants tet(K), tet(L) and tet(M) (Table 2).
Bacterial cells were lysed, and PCR was per-
formed as previously described [16]. All 12
isolates of S. pneumoniae that were resistant to
tetracycline (MIC90 64 mg ⁄L) were found to
express the tet(M) ribosomal protection
mechanism, which was consistent with the mino-
cycline MIC90 of 16 mg ⁄L. This finding was
similar to those of Izdebski et al., who found only
tet(M) to be responsible for tetracycline resistance
among S. pneumoniae isolated in Poland [17]. The
presence of the tet(M) resistance determinant in
S. pneumoniae did not alter the susceptibility to
tigecycline of these strains (MIC90 0.06 mg ⁄L).
No strains of MRSA were isolated during this
study. All the methicillin-susceptible S. aureus
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(MSSA) isolates were susceptible to tigecycline
(MIC90 0.25 mg ⁄L), minocycline (MIC90 0.25
mg ⁄L) and imipenem (MIC90 £0.06 mg ⁄L). How-
ever, a wide range of MICs of tetracycline,
levofloxacin and azithromycin were seen, indicat-
ing some resistance to these antibiotics among
these strains of MSSA.
All of the clinical isolates of H. influenzae were
inhibited by 1 mg ⁄L tigecycline or less
(MIC90 0.5 mg ⁄L). All of the H. influenzae strains
isolated in this study were fully susceptible to the
comparative agents as well: minocycline, tetracy-
cline, levofloxacin, imipenem, ceftazidime and
azithromycin. In addition, tigecycline also dem-
onstrated good activity against H. parainfluenzae
(MIC range 0.12–0.5 mg ⁄L) and Moraxella catarrh-
alis (MIC range 0.06–0.12 mg ⁄L).
Tigecycline has also demonstrated good activ-
ity against Gram-negative bacterial pathogens,
especially the Enterobacteriaceae (Table 1). Tigecy-
cline was active against strains of Escherichia coli,
with all isolates being inhibited by 0.25 mg ⁄L or
less. For K. pneumoniae, the MIC90 of tigecycline
was 1 mg ⁄L. In contrast, a wide range of MIC
values was obtained for minocycline, tetracycline,
ceftazidime and tobramycin. The presence of an
ESBL was confirmed in isolates of Escherichia coli,
K. pneumoniae or Proteus mirabilis, resulting in a
ceftazidime MIC of ‡2 mg ⁄L, determined using
Etest ESBL strips containing either ceftazidime or
cefotaxime, with and without clavulanic acid,
according to the manufacturer’s instructions (AB
Biodisk, Solna, Sweden). Two isolates of K. pneu-
moniae were confirmed to be ESBL-producing
strains. Both isolates were fully susceptible to
tigecycline (MICs of 0.5 and 1 mg ⁄L).
Table 1. In vitro activity of tigecycline and comparative
agents against isolates from patients enrolled in phase 3
clinical trials for community-acquired pneumonia
Organism (n) Antibiotic
MIC (mg ⁄L)
Range 50% 90%
Streptococcus pneumoniae (184) Tigecycline 0.03–0.12 0.06 0.06
Minocycline £0.12–32 £0.12 0.25
Tetracycline 0.06–64 0.25 0.5
Levofloxacin 0.25–2 1 1
Penicillin £0.015–8 £0.015 1
Ceftazidime £0.12–64 0.25 8
Imipenem £0.06–1 £0.06 0.25
Vancomycin 0.12–0.5 0.5 0.5
Linezolid 0.5–2 1 2
Azithromycin £0.12 to ‡64 £0.12 £0.12
S. pneumoniae (PSSP) (154) Tigecycline 0.03–0.12 0.06 0.06
Minocycline £0.12–16 £0.12 0.25
Tetracycline 0.06–64 0.25 0.5
Levofloxacin 0.25–2 1 1
Penicillin £0.015–0.06 £0.015 0.03
Ceftazidime £0.12–2 0.25 0.5
Imipenem £0.06 £0.06 £0.06
Vancomycin 0.12–0.5 0.5 0.5
Linezolid 0.5–2 1 2
Azithromycin £0.12–64 £0.12 £0.12
S. pneumoniae (PISP) (15) Tigecycline 0.06 0.06 0.06
Minocycline £0.12–32 0.25 16
Tetracycline 0.12–64 0.25 32
Levofloxacin 0.5–1 1 1
Penicillin 0.12–1 0.5 1
Ceftazidime 0.5–16 4 16
Imipenem £0.06–0.5 £0.06 0.25
Vancomycin 0.25–0.5 0.5 0.5
Linezolid 0.5–2 1 1
Azithromycin £0.12 to ‡64 £0.12 ‡64
S. pneumoniae (PRSP) (15) Tigecycline 0.03–0.12 0.06 0.12
Minocycline £0.12–1 0.25 0.25
Tetracycline 0.12–16 0.5 0.5
Levofloxacin 0.5–2 1 1
Penicillin 2–8 4 4
Ceftazidime 8–64 16 16
Imipenem 0.25–1 0.25 1
Vancomycin 0.25–0.5 0.5 0.5
Linezolid 0.5–2 1 2
Azithromycin £0.12 to ‡64 £0.12 32
Staphylococcus aureus (MSSA) (25) Tigecycline 0.12–0.25 0.12 0.25
Minocycline £0.12–0.5 £0.12 0.25
Tetracycline 0.12–32 0.25 1
Levofloxacin £0.12–16 £0.12 0.25
Oxacillin £0.25–1 0.5 1
Ceftazidime 4–16 8 16
Imipenem £0.06 £0.06 £0.06
Vancomycin 1–2 1 2
Linezolid 2–4 2 4
Azithromycin 0.5 to ‡64 1 2
Tobramycin £0.25–2 £0.25 0.5
Haemophilus influenzae (39) Tigecycline 0.06–1 0.25 0.5
Minocycline £0.12–0.5 0.25 0.5
Tetracycline 0.25–1 0.5 0.5
Levofloxacin £0.12 £0.12 £0.12
Ceftazidime £0.12–0.25 £0.12 £0.12
Imipenem £0.06–2 0.5 2
Azithromycin 0.25–4 1 2
Tobramycin £0.25–2 1 2
H. parainfluenzae (20) Tigecycline 0.12–0.5 0.25 0.5
Minocycline 0.5–2 0.5 1
Tetracycline 0.25–16 0.25 0.5
Levofloxacin £0.12 £0.12 £0.12
Ceftazidime £0.12–2 £0.12 0.25
Imipenem £0.06–1 0.12 0.5
Azithromycin £0.12–2 0.5 1
Tobramycin £0.25–2 1 1
Moraxella catarrhalis (9) Tigecycline 0.06–0.12 NA NA
Minocycline £0.12 NA NA
Tetracycline 0.12–0.5 NA NA
Levofloxacin £0.12 NA NA
Ceftazidime £0.12–0.25 NA NA
Imipenem £0.06–0.12 NA NA
Azithromycin £0.12 NA NA
Tobramycin £0.25–0.5 NA NA
Table 1. Continued
Organism (n) Antibiotic
MIC (mg ⁄L)
Range 50% 90%
Escherichia coli (8) Tigecycline 0.06–0.25 NA NA
Minocycline 0.5–2 NA NA
Tetracycline 1–64 NA NA
Levofloxacin £0.12 NA NA
Ceftazidime £0.12–0.25 NA NA
Imipenem £0.06–0.25 NA NA
Tobramycin 0.5–1 NA NA
Klebsiella pneumoniae (15) Tigecycline 0.25–2 1 1
Minocycline 2–8 4 8
Tetracycline 1 to ‡64 2 64
Levofloxacin £0.12–4 £0.12 0.5
Ceftazidime £0.12–32 0.25 16
Imipenem £0.06–4 0.25 1
Tobramycin £0.25–32 0.5 16
NA, not applicable, fewer than ten isolates; PSSP, penicillin-susceptible S. pneumo-
niae; PISP, penicillin-intermediate S. pneumoniae; PRSP, penicillin-resistant S. pneu-
moniae; MSSA, methicillin-susceptible S. aureus.
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Repeat cultures during or after therapy were
performed on respiratory secretions at the discre-
tion of the investigator. No isolate of any genus
became resistant following treatment with tigecy-
cline. This is not surprising, because it was shown
that tigecycline did not select for resistant
mutants of S. pneumoniae after multiple sequential
subcultures [18].
In summary, the in vitro activity of tigecycline
against a broad spectrum of Gram-positive and
Gram-negative aerobic and anaerobic pathogens
isolated from patients enrolled in phase 3 clinical
trials conducted worldwide showed an excellent
susceptibility profile and suggests its utility in the
treatment of patients with community-acquired
pneumonia.
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